Loading clinical trials...
Loading clinical trials...
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) in Subjects With Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion
Conditions
Interventions
Apremilast 20mg
Apremilast 30mg
+1 more
Locations
91
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Elite Clinical Studies, LLC
Phoenix, Arizona, United States
Catalina Pointe Clinical Research Incorporated
Tucson, Arizona, United States
Bakersfield Dermatology and Skin Cancer Medical Group
Bakersfield, California, United States
Dermatology Research Associates
Los Angeles, California, United States
Desert Medical Advances
Palm Desert, California, United States
Start Date
September 30, 2010
Primary Completion Date
August 21, 2012
Completion Date
February 9, 2017
Last Updated
May 6, 2020
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
NCT07315061
Lead Sponsor
Amgen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions